Maker of Weight Loss and Menopause Supplement Settles Deceptive Marketing Charges
An FTC complaint claims that Lunada Biomedical didn't have any clinical evidence that its products actually worked
The maker of a weight loss and menopause supplement is settling Federal Trade Commission (FTC) charges that the company failed to have evidence to back-up its claims.
The settlement bans Lunada Biomedical and its owners from making misleading claims about the effectiveness of its supplements unless it has the clinical data to back them up. It also hands down a $40 million judgement, but due to its inability to pay, Lunada is only responsible for $250,000.
The FTC's complaint alleges that the defendants made unsubstantiated claims that their dietary supplement, Amberen, causes substantial and sustained weight loss, loss of belly fat, and an increase in metabolism in women over 40 who are perimenopausal or menopausal.
The FTC also alleges that the defendants made unsubstantiated claims that Amberen alleviates nearly every common symptom of menopause, including hot flashes, night sweats, sleep problems, fatigue, and irritability—but had no evidence to back up these claims.
The FTC also says that Lunada failed to disclose its relationship with certain endorsers and falsely claimed customer satisfaction and success rates of 93 percent.
The company also falsely advertised that customers could try Amberen risk free for 30 days.
"The Lunada defendants made strong claims about the effectiveness of their supplement without the scientific evidence to back them up," said Jessica Rich, Director of the FTC's Bureau of Consumer Protection. "The relief provided by this court order is intended to prevent the defendants from making unsupported health benefit claims in the future."